Depression research published in 2025 (page 6)

Esketamine for Treatment-Resistant Depression in Pakistan: A Promising Strategy

Hospital Pharmacy October 23, 2025 Moomal Memon, Rukhsana Gul, Arif Gul et al. 1 citation

Depression, projected to be the leading cause of global disability by 2030, affects up to 19.62% of Pakistan's population. Treatment-resistant depression (TRD), characterized by poor response to at least two antidepressants, poses a major clinical challenge. Although interventions like ECT exist, their use is limited by systemic barriers. Esketamine, an NMDA receptor antagonist, offers a...

DOI: 10.1177/00185787251384516 Ketamine Treatment-resistant depression Major depressive disorder Psychological intervention +8

Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression

JAMA Psychiatry October 22, 2025 A. Jelovac, Cathal Mccaffrey, Masashi Terao et al. 13 citations

Key Points Question For inpatients with moderate to severe depression, is repeated intravenous ketamine superior to a psychoactive placebo (midazolam) in reducing depressive symptoms? Findings In this randomized clinical trial, there was no statistically significant difference in the primary outcome, end-of-treatment Montgomery-Åsberg Depression Rating Scale score, between the ketamine and...

DOI: 10.1001/jamapsychiatry.2025.3019

EFFECT OF MINDFULNESS MEDITATION & PRANAYAMA ON PATIENTS WITH CHRONIC DEPRESSION

The Social Science Review A Multidisciplinary Journal October 20, 2025 S. Bose, Amjad Ali

Depression is a major cause of disability across the world, and influences not only emotional but also cognitive health. Although medication and psychotherapy are the main approaches in treating depression, the effect of alternative methods such as mindfulness meditation and pranayama (yogic breathing techniques) have shown to be beneficial to reduce depressive symptoms. Mindfulness meditation,...

DOI: 10.70096/tssr.250307067

Esketamine Nasal Spray for Treatment-Resistant Bipolar II Depression: A Case Report

Psychiatry Investigation October 15, 2025 Hong-Ci Lin, Chia-Yu Chang, Ching-Huang Lin et al. 1 citation

This case report discusses a 62-year-old male with treatment-resistant bipolar II depression and hypertension. After poor responses to multiple treatments, an add-on esketamine nasal spray (ESK-NS) was introduced in October 2022. Improvement was seen, and the patient's depressive episode was nearly remitted during the maintenance phase. However, recurrence was noted when ESK-NS frequency was...

DOI: 10.30773/pi.2024.0312 Full text

Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS study.

Journal of Affective Disorders October 15, 2025 Mary Lou Chatterton, Johana Kevin Perez, Thao Thai et al. 2 citations

Ketamine is effective for treatment resistant depression (TRD); but cost-effectiveness evidence remains limited. To evaluate the cost-effectiveness of subcutaneous ketamine for TRD from health sector and societal perspectives. A cost-utility analysis alongside the KADS randomised controlled trial (RCT) involved 174 participants receiving ketamine or midazolam (active control) twice weekly for 4...

DOI: 10.1016/j.jad.2025.119502 Full text Treatment-resistant depression Major depressive disorder Clinical trials Clinical drug studies +5

Reperceiving depression: how trait mindfulness enhances perceived support through improved doctor–patient relationships and stigma alleviation in depressed young adults

Frontiers in Psychology October 14, 2025 Danhong Zhu, Yufeng Yang, Jing Wen et al.

ObjectiveDepression, a prevalent mental health disorder among global youth, adversely impacts educational attainment, social functioning, and psychological wellbeing. Given the established protective function of perceived social support against depressive symptoms, this study investigates how trait mindfulness enhances such support through three mediating factors: therapeutic alliance...

DOI: 10.3389/fpsyg.2025.1589931

Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release.

European Psychiatry October 14, 2025 Andreas Reif, Bernhard T Baune, Jozefien Buyze et al.

Clinical response and remission may not fully reflect patient priorities in treatment-resistant depression (TRD). Health-related quality-of-life (HRQoL) outcomes should be assessed to comprehensively capture treatment benefits. ESCAPE-TRD (NCT04338321) was a 32-week randomized, phase IIIb trial comparing esketamine nasal spray (NS) versus quetiapine extended release (XR), both alongside an...

DOI: 10.1192/j.eurpsy.2025.10123 Full text Esketamine Treatment-resistant depression Clinical trial Quetiapine

LSD: Mechanisms and relevance to the treatment of depression

Neuroscience & Biobehavioral Reviews October 10, 2025 Amel Bouloufa, Sarah Delcourte, Thomas Delannay et al. 3 citations

Major depressive disorder (MDD) is one of the most prevalent psychiatric conditions worldwide, affecting over 350 million people. Standard treatments, primarily antidepressants targeting serotonin, noradrenaline, and/or dopamine, are based on the monoamine hypothesis, which links depression to imbalances in these neurotransmitters. A sizable fraction of patients, however, does not get enough...

DOI: 10.1016/j.neubiorev.2025.106407 Major depressive disorder Serotonergic Anxiety Neuroplasticity +10

Control group improvement lower in psilocybin trials for depression

The Brown University Psychopharmacology Update October 10, 2025

A meta‐analysis comprising 17 randomized trials has found that rates of control group improvement in depression studies were lower in psilocybin trials than in studies of esketamine or a selective serotonin reuptake inhibitor (SSRI). The results suggest that psilocybin's overall efficacy in the treatment of depression might be overestimated.

DOI: 10.1002/pu.31371 Psilocybin Treatment-resistant depression Depression economics Serotonin reuptake inhibitor +4

Perceptions of a mindfulness-based cognitive therapy intervention: Focus group findings examining acceptability for African Americans with epilepsy.

Epilepsy & Behavior October 9, 2025 Robin E McGee, Elizabeth I Ojemakinde, Nancy J Thompson et al.

Depression commonly co-occurs in people with epilepsy (PWE). Reducing depression in PWE may contribute to improved quality of life and outcomes. Project UPLIFT, a distance-delivered, mindfulness-based cognitive therapy program has reduced depressive symptoms among PWE. Little is known about the acceptability of the program among African Americans with epilepsy. Thus, we conducted a formative...

DOI: 10.1016/j.yebeh.2025.110755 Depression Humans Epilepsy Focus groups +9

Mindfulness, Depression, and Fall Risk in Low-Income Older Adults

Research in Health and Medicine October 8, 2025 Aleeyah Uddeen, Janet Lopez, Renata Komalasari et al. 1 citation

Introduction: Mindfulness, through mind-body practices, promotes awareness and presence. Its practice, along with reduced depression, may improve balance and lower fall risk in older adults. This study examined the association between mindfulness, depression, and fall risk among low-income, community-dwelling older adults. Methods: A descriptive cross-sectional study was conducted with 103...

DOI: 10.53520/rdhs2025.104164

“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy

Psychedelic Medicine October 8, 2025 Elise C. Tarbi, Skye A. Miner, Kabir Nigam et al. 1 citation

Background: Cancer poses an existential threat for patients and caregivers. Psilocybin-assisted therapy (PAT) has emerged as a potential tool to meet these existential needs, yet little is known about how patients describe this element of their cancer journey, and how it might be affected by PAT, especially in the group therapy context. Purpose: To explore how patients with cancer and...

DOI: 10.1177/28314425251370303 Psilocybin Existentialism Cancer Perspective graphical +6

Adolescents' trajectories of mental health in the MYRIAD trial.

JCPP Advances October 7, 2025 Carolina Guzman Holst, Simona Skripkauskaite, Jack L. Andrews et al.

This study explored adolescent's mental health trajectories over the course of a school-based mindfulness-based intervention trial (MYRIAD). It examined whether intervention condition (mindfulness vs. teaching-as-usual), individual-level and contextual-level factors were associated with different trajectories. This pre-registered study used data from 11- to 14-year-olds who participated in the...

DOI: 10.1002/jcv2.70046 Full text Depression Adolescence Mindfulness training School-based interventions +1

Effects of Mindfulness Training on Depression and Cognition in Older People With Mild Cognitive Impairment: A Systematic Review and Meta‐Analysis

Journal of The American Geriatrics Society October 6, 2025 Edgar Vásquez-Carrasco, B. H. Branco, Jordan Hernandez-Martinez et al.

This systematic review and meta‐analysis aimed to evaluate the efficacy of mindfulness‐based treatments for older people with mild cognitive impairment (MCI) who also experience depression and cognitive difficulties.

DOI: 10.1111/jgs.70154 Full text

The effect of mindfulness-based couple-centered intervention in parents following fetal abnormalities requiring pregnancy termination: study protocol for a randomized controlled trial.

BMC Pregnancy and Childbirth October 2, 2025 Shiwen Sun, Jialu Qian, Yaping Sun et al.

BACKGROUND: Termination of pregnancy for fetal abnormalities (TOPFA) represents a significant global healthcare challenge. In China, the occurrence of fetal abnormalities is notably high. TOPFA is a devastating traumatic event for parents and families. Parents frequently encounter psychological issues and negative emotions such as depression, anxiety, prolonged grief, feelings of inadequacy,...

DOI: 10.1186/s12884-025-08138-2 Full text Depression Anxiety Mindfulness Humans +10

Effectiveness of a Mindfulness-Based Mobile Intervention for Improving Perinatal Mental Health and Reducing Depression During Pregnancy: Randomized Controlled Trial.

Journal of Medical Internet Research October 2, 2025 Minjung Kim, Jin Young Park, Sehwan Park et al.

Background: Pregnancy is a vulnerable period for women, with an increased risk of mental health issues such as depression and anxiety. The perinatal period is particularly important, as maternal mental health significantly impacts maternal physical health, pregnancy outcomes, postnatal outcomes, and fetal and infant development. Psychotherapeutic interventions for depression are essential,...

DOI: 10.2196/75630 Full text Depression Humans Pregnancy complications Mental health +6

Synergistic effects of capsaicin and ketamine on the depression-like behaviors of animals subjected to the chronic unpredictable mild stress protocol.

Physiology & Behavior October 1, 2025 Irving Aguilar-Martínez, J. Góngora-Alfaro, R. Navarro-Polanco et al.

A significant percentage of depression patients are resistant to pharmacological treatments, highlighting the need for novel antidepressant strategies. Ketamine, an NMDA receptor antagonist, produces rapid antidepressant effects and is effective in treatment-resistant cases, but its association with cognitive and behavioral abnormalities resembling schizophrenia limits broader clinical utility....

DOI: 10.1016/j.physbeh.2025.115122

Efficacy and safety of ketamine maintenance therapy in treatment-resistant depression: A systematic review of treatment protocols and clinical outcomes.

Journal of Affective Disorders October 1, 2025 A. M. Al-Garni, Gustavo Vazquez, Tariq Alotibi et al.

INTRODUCTION Treatment-resistant depression (TRD) represents a significant therapeutic challenge, as conventional treatments demonstrate limited efficacy. Although ketamine's acute antidepressant effects are well-documented, the role of maintenance therapy remains understudied. We conducted a systematic review to assess the efficacy, safety, and optimal implementation strategies of ketamine...

DOI: 10.1016/j.jad.2025.120475

Experteninterview zum Thema psychedelisch unterstützte Psychotherapie (PAP) bei Patienten mit behandlungsresistenter Depression (TRD)

Psychotherapie-Wissenschaft October 1, 2025 Jean Schulthess Watt

Eine Gruppe von Patienten, die schlecht auf Psychotherapie und Medikamente ansprechen, sind Patienten mit der Diagnose einer behandlungsresistenten Depression (TRD). Ein relativ neuer und erfolgreicher Psychotherapieansatz, der auch an der Psychiatrischen Klinik Münsterlingen unter der Leitung von Dr. Krähenmann (Ärztlicher Direktor der Psychiatrischen Dienste Thurgau) umgesetzt wird, ist das...

DOI: 10.30820/1664-9583-2025-2-23

Methodological considerations for interpreting ketamine-naltrexone trials in depression

The International Journal of Neuropsychopharmacology October 1, 2025 Igor D. Bandeira, Luke A. Jelen, Jason M Tucciarone et al. 4 citations

Igor D Bandeira, MD, PhD, Luke A Jelen, MD, PhD, Jason M Tucciarone, MD, PhD, Boris D Heifets, MD, PhD, Carolyn I Rodriguez, MD, PhD, Alan F Schatzberg, MD

DOI: 10.1093/ijnp/pyaf073 Full text Depression economics Medline Clinical trial Clinical neurology +1

Studies